Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 10,000 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 10,000 shares of the firm’s stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $70.18, for a total transaction of $701,800.00. Following the completion of the transaction, the insider now directly owns 523,904 shares of the company’s stock, valued at approximately $36,767,582.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Derek J. Maetzold also recently made the following trade(s):

  • On Monday, April 26th, Derek J. Maetzold sold 14,374 shares of Castle Biosciences stock. The shares were sold at an average price of $69.17, for a total transaction of $994,249.58.

NASDAQ CSTL opened at $71.22 on Friday. The business’s 50-day moving average is $63.70. The firm has a market cap of $1.78 billion, a PE ratio of -100.31 and a beta of 0.42. Castle Biosciences, Inc. has a 52-week low of $34.72 and a 52-week high of $107.69.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Sunday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $22.81 million during the quarter, compared to analysts’ expectations of $16.66 million. Castle Biosciences had a negative net margin of 22.24% and a negative return on equity of 4.74%. Castle Biosciences’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 EPS. Equities research analysts forecast that Castle Biosciences, Inc. will post -0.92 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in shares of Castle Biosciences by 13.0% during the 1st quarter. Principal Financial Group Inc. now owns 88,564 shares of the company’s stock worth $6,063,000 after buying an additional 10,212 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of Castle Biosciences during the 1st quarter worth about $300,000. Voloridge Investment Management LLC lifted its stake in shares of Castle Biosciences by 16.1% during the 1st quarter. Voloridge Investment Management LLC now owns 41,070 shares of the company’s stock worth $2,812,000 after buying an additional 5,692 shares during the last quarter. Grandeur Peak Global Advisors LLC lifted its stake in shares of Castle Biosciences by 346.1% during the 1st quarter. Grandeur Peak Global Advisors LLC now owns 39,339 shares of the company’s stock worth $2,693,000 after buying an additional 30,520 shares during the last quarter. Finally, Select Equity Group L.P. acquired a new stake in shares of Castle Biosciences during the 1st quarter worth about $24,651,000. Institutional investors own 84.99% of the company’s stock.

A number of research analysts recently weighed in on CSTL shares. Lake Street Capital started coverage on shares of Castle Biosciences in a research report on Friday, April 30th. They issued a “buy” rating and a $94.00 target price for the company. Zacks Investment Research upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, May 10th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $73.00 price target on shares of Castle Biosciences in a research note on Thursday, May 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $80.29.

About Castle Biosciences

Castle Biosciences, Inc, a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue.

Recommended Story: What is the outlook for the FAANG stocks?

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.